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Abstract
Background: Pelizaeus-Merzbacher disease (PMD) is an X-linked dysmyelinating disorder characterized by
nystagmus, hypotonia, ataxia, progressive spasticity, and cognitive decline. PMD classically results from a duplication
of a genomic segment encompassing the entire PLP1 gene. Since the PLP1 gene is located in Xq22, PMD affects
mostly boys.
Methods and results: Here we report the case of a girl with typical PMD. Copy number analysis of the PLP1 locus
revealed a duplication of the entire gene and FISH analysis showed that the extra copy of the PLP1 gene was
actually inserted in chromosome 1p36. This insertion of an additional copy of PLP1 in an autosome led to a
functional duplication irrespective of the X-inactivation pattern. Subsequent overexpression of PLP1 was the cause
of the PMD phenotype observed in this girl. Further sequencing of the breakpoint junction revealed a
microhomology and thus suggested a replication based mechanism (such as FoSTeS or MMBIR).
Conclusion: This case emphasizes the susceptibility of the PLP1 locus to complex rearrangement likely driven by
the Xq22 local genomic architecture. In addition, careful consideration should be given to girls with classical PMD
clinical features since they usually experience complex PLP1 genomic alteration with a distinct risk of inheritance.
Background
Pelizaeus-Merzbacher disease (PMD; MIM#312080) is a
rare X-linked hypomyelinating leukodystrophy related to
genomic alterations of the proteolipid protein 1 (PLP1)
gene [1]. PLP1 encodes both major proteins of the cen-
tral nervous system (CNS) myelin, PLP and DM20.
PMD is characterized by early nystagmus, hypotonia and
ataxia with subsequent signs of neurodegeneration char-
acterized by severe spasticity and cognitive impairment.
However, a large clinical spectrum exists from severe
forms without motor acquisitions and dystonia (PMD0),
to mild forms with acquired walking capacities (PMD3),
and the mildest form of PLP-pathies, spastic paraplegia
type 2 (SPG2, MIM#312920). An obvious genotype-
phenotype correlation has been described in PMD.
Missense mutations are rare but usually cause the most
severe forms, whereas PLP1 loss-of-function alterations
(null mutations and large deletions) lead to the mildest
PMD/SPG2 forms. Classical PMD is commonly caused by
duplication of a genomic segment containing the entire
PLP1 gene. PLP1 gene duplication results in PLP overex-
pression and subsequent accumulation in the cytoplasm
of the myelinating oligodendrocytes leading to cellular
stress and CNS myelin defect. A gain of three to five cop-
ies of the PLP1 gene have been rarely described and are
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associated with a severe phenotype [2, 3]. PMD affects al-
most exclusively boys and most females who carry and
transmit PLP1 genomic alterations to their affected sons
are asymptomatic or manifest mild, late-onset spastic
paraplegia or cognitive impairment. Few cases of girls
presenting a phenotype of PMD in childhood have been
described. Foncesca et al. reported the case of a consti-
tutional translocation t(X;22)(q22;q13) with an add-
itional PLP1 copy at the breakpoint region in a girl with
classical PMD [4]. Yiu et al. reported another case of a
PMD girl with an unbalanced chromosomal translocation
of PLP1 into 1p36 [5]. Additional cases of girls with PMD
due to very large PLP1 gene duplications have been re-
ported [6].
Here we report the case of a 2 year old girl with typical
PMD who has an insertion of an extra copy of a gen-
omic segment of Xq22 containing the entire PLP1 gene
into chromosome 1p36. This insertion of an additional
active copy of PLP1 in an autosome led to a functional
duplication. Further delineation of the breakpoint junc-
tion sequence revealed a microhomology and thus sup-
port a replication based mechanism such as FoSTeS and
MMBIR. Our result further emphasizes the large diver-
sity of the genomic rearrangement involving the PLP1
gene probably based on the complexity of the genomic
architecture [7].
Methods
Multiplex ligation-dependent probe amplification (MLPA)
MLPA was conducted according to the supplied manu-
facturer’s specifications using the probemix P022-PLP1
(MRC-holland, Amsterdam, Holland). PCR products
were then mixed with formamide (HiDi Formamide, Ap-
plied Biosystems, Foster City, CA) and fluorescent Gen-
escan 500 LIZ size standard (Applied Biosystems) prior
to analysis using an Applied Biosystems ABI 3130xl ca-
pillary sequencer (Applied Biosystems). Data collection
and export used GeneMapper software (Applied Biosys-
tems). Peak areas of each fragment were compared to
those of a control sample to calculate the gene dosage of
each amplicon, including those corresponding to each
exon of the PLP1 gene.
X chromosome inactivation pattern
The analysis of the X inactivation pattern was based on
extend human androgen receptor (HUMARA) assay
proposed Bertelsen et al. [8]. Briefly, 200 ng of leukocyte
DNA was digested with HpaII (New England Biolabs,
Ipswich, MA) at 37 °C for 12 h. PCR amplification of
four loci (AR, PCSK1N, SLITRK4, and ZDHHC15) was
performed on undigested DNA and HpaII digested
DNA. PCR products were subsequently analyzed on an
ABI 3130xl Genetic Analyzer (Applied Biosystems) using
GeneMapper software (Applied Biosystems). The X-
inactivation ratios were calculated as previously described
and skewed X chromosome inactivation was considered if
this ratio decrease below 20 % in the investigated blood
sample [8].
PLP1 gene expression analysis in patient fibroblasts
Total RNA was isolated from fibroblasts of eight con-
trols without copy number variation of the PLP1 gene,
of one positive control with a duplication of PLP1, and
of our patient using the guanidinium thiocyanate-
phenol-chloroform method. Ten microgram was used to
generate cDNA using Superscript II first-strand cDNA
synthesis kit (Invitrogen, Carlsbad, CA, USA) with oligo
(dT) primers, according to the manufacturer’s protocol.
Our patient and control cDNAs were used for PLP1
gene expression analysis performed by real-time PCR ac-
cording to previously reported conditions [9]. Specific-
ally designed primers were used to determined total
PLP1 gene expression after normalization to the beta-
glucuronidase gene (GUSB) expression using the ΔΔCt
method.
Microarray
Creation of a custom array CGH design was performed
using the Agilent software eArray (https://earray.chem.
agilent.com/earray/), referred to the GRCh37/hg19 as-
sembly to cover the PLP1 genomic region with max-
imum resolution. The microarray contained a total of
30,032 probes spanning a 20 Mb region surrounding the
PLP1 gene (Agilent Technologies, Santa Clara, CA).
Those 30,032 probes were distributed between three
groups with various probe densities. The first group
includes 15,032 probes encompassing 2 Mb (chrX:
102,000,000–104,000,000; corresponding to a 150 bp
average probe spacing) around the PLP1 gene and in-
cludes most of the PLP1 duplications described so far
[10, 11]. A second, largest interval contained 10,000
probes surrounding 8 Mb (chrX: 98,000,000–102,000,000
and chrX: 104,000,000–106,000,000; 800 bp average
probe spacing). The last interval was designed to en-
compass the largest PLP1 rearrangement and includes
5,000 probes spanning 10 Mb (chrX: 93,000,000–
98,000,000 and chrX: 106,000,000–113,000,000; 2000 bp
average probe spacing) [6].
A HumanCytoSNP-12 (V2.1) pangenomic microarray
(Illumina, San Diego, CA USA) was also performed.
Fluorescence in situ hybridization (FISH)
Fluorescence in situ hybridization (FISH) was performed
on lymphocytes metaphase spreads according to stand-
ard protocols. FISH analysis was carried out with the
probe RP11-832L2 spanning 183 Kb (chrX:102,902,650–
103,085,315), which encompasses the entire PLP1 gene,
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together with a subtelomeric probe of the short arm of
chromosome 1 (CEB108/T7).
Genome walker
The Universal Genome Walking Kit (Clontech, Palo
Alto, CA, USA) was used to identify precise break-
points of the inserted PLP1-containing X chromosome
segment into 1p36. According to the manufacturer’s
protocol, the genomic DNA of the patient was com-
pletely digested with four separate restriction enzymes
(i.e. EcoRV, DraI, PvuII, and SspI) and subsequently li-
gated to the GenomeWalker adaptors. The Genome-
Walker libraries produced were then used as a template
for primary PCR amplification. The primers used were
the outer adaptor primer provided in the kit and a
Xq22 specific primer localized at the boundaries of the
duplicated PLP1 segment identified with our highly
resolutive PLP1-custom array CGH. A secondary
nested PCR using the nested adaptor primer and a
nested Xq22 specific primer was then performed. Se-
quencing of the PCR products was finally achieved if a
single or two (considering that both, the normal Xq22
and the 1p36 derivative, alleles could be digested and li-
gated to the adaptor) specific and major PCR products
were visible after electrophoresis through an agarose
gel stained with GelRed (Biotium, Hayward, CA, USA).
Sequencing was conducted using the nested primers




Here we report the case of a girl who is the third child
from unrelated and healthy parents of Greek origin. Preg-
nancy was uneventful, however during the second month
of life a horizontal nystagmus and severe hypotonia were
noticed. At 9 months of age, a brain magnetic resonance
imaging (MRI) was performed due to a persistent delay in
motor milestones associated with ataxia of the head and
trunk led; MRI revealed a severe delay in the myelination
process (evaluated at 2 months of age). Afterwards, she
improved obviously in motor capacities (holding her head
up at 12 months, sitting with support at 16 months, and
standing position at 30 months) with excellent psycho-
social interactions and decreased nystagmus intensity. An-
other brain MRI at 33 months of age confirmed the
diffuse “hypomyelinating” pattern of the supratentorial
cerebral white matter (Fig. 1). In addition, brainstem audi-
tory evoked potentials showed an exclusive cochlear wave
I without subsequent recordable brain waves suggesting a
severe impairment in CNS conduction. No other abnor-
malities including dysmorphic features, heart, kidney, or
liver problems were found. Now aged 4 years, she con-
tinues to improve (crawling, walking with support, feeding
herself, drawing a line, speaking using comprehensive sim-
ple sentences). However, signs of pyramidal tract dysfunc-
tions are clearly present in the lower limbs and MRI
abnormalities have not changed. Those clinical features
strongly suggested the diagnosis of PMD.
Fig. 1 Patient’s brain magnetic resonance imaging (MRI). Sagittal T1-weighted MRI showed iso/hyposignal of the whole cerebral white matter,
axial T2-weighted, and FLAIR images showing diffuse hypersignal of the hemispheric white matter, internal capsule, and corpus callosum in the
patient at 2.5 years compared to an age-matched healthy child
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Characterization of the PLP1 gene duplication
MLPA analysis of the DNA extracted from the patient’s
blood revealed a duplication of the seven probes local-
ized in each coding exon of the PLP1 gene. Additional
probes that were duplicated revealed that the duplication
extended at least from the TCEAL1 to ESX1 genes thus
encompassing at least 614 Kb (but less than 1685 Kb).
To confirm the PLP1 duplication and define more pre-
cisely the size of the duplicated segment we used a custom
array CGH (aCGH) designed to encompass the Xq22 gen-
omic region containing the PLP1 gene with maximum
resolution. The aCGH profile confirmed the MLPA result
and specified the breakpoint of the duplicated genomic
segment covering from 102,761,000 to 103,513,000 (752
Kb of length) on Xq22 according to the GRCh37/hg19 as-
sembly (Fig. 2a).
We next performed FISH analysis with a BAC probe
specific to the PLP1 locus (RP11-832L2, Xq22.2) on
lymphocyte metaphase spreads. Three distinct PLP1-
specific signals were visualized consistent with the PLP1
duplication in a girl. Two probes bound to the normal
Xq22 band of both X chromosomes together with an add-
itional ectopic signal that bound just proximal to the
CEB108/T7 1p36 subtelomeric probe (Fig. 2b). Another
FISH analysis with BAC probes localized to X chromo-
some telomeres did not reveal a translocation involving
the X chromosome. Hence, the additional copy of PLP1
results from an insertion into chromosome 1p36 rather
than a classical translocation. A whole genome microarray
confirmed the PLP1 duplication but did not reveal any
copy number alteration in 1p36 region. MLPA analysis
in the parents did not reveal any variation in PLP1 copy
Fig. 2 Insertion of an Xq22 segment including PLP1 in 1p36. a Custom PLP1 array CGH profile confirms the PLP1 gene (centered on the blue bar)
duplication and precise the breakpoint of the duplicated genomic segment expanding from 102,761,000 to 103,513,000 (752 Kb of length) on
Xq22 (the red arrow indicates the embedded triplicated segment). b FISH analysis with the RP11-832L2 PLP1-specific and the CEB108/T7 1p36
subtelomeric probes reveals that the additional PLP1 copy is inserted into autosome 1p36. c Sequencing of a breakpoint of the insertion of
PLP1-containing segment in 1p36 chromosome reveals a two-base pair microhomology
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number. However, we wondered if this rearrangement
was nevertheless inherited from a parental balanced re-
arrangement. Therefore we performed the PLP1 specific
FISH analysis on the parents’ blood and did not detect
any ectopic localization of the PLP1 gene. We thus con-
clude that this rearrangement was acquired either in the
gametes of one of the parents or de novo.
Absence of skewed X inactivation pattern
A skewed X inactivation pattern resulting in inactivation
of the X chromosome carrying the abnormal PLP1 gene
has been suggested to explain why most females who
carry PLP1 genomic alteration are asymptomatic [12].
We thus performed an analysis of the X inactivation pat-
tern based on the extend HUMARA assay [8]. This ana-
lysis of DNA extracted from a blood sample from the
patient did not reveal a significant skewed pattern for
any of the four X chromosome loci explored (i.e. AR,
PCSK1N, SLITRK4, and ZDHHC15). Although we can-
not assert that there is not a skewed X chromosome in-
activation pattern in the oligodendrocytes of the patient,
the insertion of an extra-copy of PLP1 in an autosome
did lead to a functional duplication irrespective of the X-
inactivation pattern.
PLP1 over-expression in patient fibroblasts
We also quantified the PLP1 gene expression in fibro-
blasts from the patient and compared it to expression in
normal control fibroblasts and fibroblasts from male pa-
tients with classical tandem PLP1 duplications. The du-
plicated controls and our patient showed a 1.88 and a
5.21-fold increase of the PLP1 expression respectively
compared to the normal control. This result confirmed
the functional duplication of the PLP1 gene leading to
its overexpression in the patient’s fibroblasts.
Precise mapping of the breakpoint using genome walking
strategy
To further characterize the insertion site of PLP1 on
chromosome 1p36, we performed a genome walking
strategy. This molecular procedure allows sequencing of
the 1p36 telomeric flanking segment directly adjacent to
the breakpoint of the duplicated genomic region of
Xq22 (Fig. 2c). The Xq22 segment inserted exactly at the
position chr1:140,332 (GRCh37/hg19) on chromosome
1p36. In addition, we identified 2 bp of microhomology
shared by the 1p36 and the Xq22 boundaries genomic
sequences.
Discussion
We have described the case of a girl with a classical form
of PMD due to an insertion of the PLP1 gene into 1p36
autosome. PLP1 gene duplication in boys results in PLP
overexpression and subsequent accumulation in the
cytoplasm of the myelinating oligodendrocytes, leading
to a CNS myelin defect. We demonstrated that the PLP1
transcript is overexpressed in the fibroblasts of our pa-
tient with an insertion of an additional copy of PLP1 in
chromosome 1p36. It has been proposed that PLP1 ex-
pression in fibroblasts is a good cellular model for
reflecting the consequences of an altered PLP1 gene dos-
age [9]. We thus assume that the additional copy of
PLP1 led to an overexpression of PLP in oligodendro-
cytes and that subsequent toxicity in this cell type was
responsible for the neurological phenotype. The PLP1
overexpression seems even higher in our patient’s fibro-
blasts compared to classical tandem duplications in boys.
This could be related to the epigenetic state of the chro-
matin environment in the 1p36 insertion site that could
be more favorable to gene expression than the Xq22
PLP1 locus.
Sequence analysis of the boundaries of the Xq22 dupli-
cated segment revealed two nucleotides of microhomology
at the telomeric breakpoint junction (Fig. 2c) consistent
with a replication based mechanism, such as fork stalling
and template switching (FoSTeS) [10] or microhomology-
mediated break-induced replication (MMBIR) [13]. We
cannot rule out that the two-base microhomology ob-
served at the breakpoint occurs by chance and is not re-
lated to a replicative-based mechanism. However, it is
noteworthy that James Lupski and colleagues firstly de-
scribed the elegant FoSTeS mechanism precisely at the
PLP1 locus [10]. Based on this model, we propose a gen-
omic mechanism to explain the microhomology-based
insertion of PLP1 in an autosome (Fig. 3): instead of
switching to a template on the sister chromatid, as it
has been classically described, the replication fork may
switch to chromosome 1p36. Indeed, in the classical
model (i.e. intrachomosomal rearrangement), both rep-
lication forks may be separated by large genomic se-
quence leading to extensive duplication or deletion. It is
reasonable to believe that the new replication fork rees-
tablish by considering the physical proximity of the new
microhomology-based site. Thus, the new replication
fork could take place on distinct chromosome if the in-
sertion site is physically close considering the three-
dimensional structure of the chromatin in interphase
nuclei. This may be supported by the fact that another
PLP1 rearrangement involving the 1p36 genomic region
has already been described [5].
Despite several primer combinations and PCR condi-
tions we were unable to obtain the second breakpoint
junction. The inability to obtain a PCR product for the
centromeric breakpoint may be related to the complexity
of the rearrangement at this breakpoint. Indeed, the
PLP1-custom aCGH revealed a triplicated segment em-
bedded in the PLP1 duplication from chrX:103,230,500
to chrX:103,317,500 (Fig. 2a). Triplications of the PLP1
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gene have already been described and are associated
with a more severe phenotype compared with patients
with duplications [2, 3]. However, in our case, the tripli-
cated segment did not include the PLP1 gene. This is con-
sistent with the mild phenotype of our patient compared
to PMD boys with three copies of PLP1. It has been pro-
posed that triplications at the PLP1 locus result from a
duplication-inverted triplication-duplication (DUP-TRP/
INV-DUP) likely based on a replication based mechanism
and that relies on the presence of segmental duplications
in an inverted orientation [14]. Interestingly, the tripli-
cated segment observed in our case occurred between two
segmental duplications encompassing the H2BFXP pseu-
dogenes localized 60 Kb from each other in an inverted
direction. This triplicated segment further illustrates the
complexity of the observed rearrangement.
Conclusion
Here we describe the case of a girl with a classical form
of PMD due to an insertion of a 752 Kb Xq22 region
containing the whole PLP1 gene into 1p36 autosome.
This rearrangement harbors a two base-pair microho-
mology at one of the breakpoint suggesting a replication
based mechanism such as FoSTeS or MMBIR. In
addition to PLP1 duplications, other genomic
rearrangements responsible for PMD, including dele-
tions [15, 16], and translocations [4] have been de-
scribed. Complex genomic rearrangements including
duplication-inverted triplications [2, 3] and complex du-
plications consisting of two duplicated fragments inter-
spersed with a segment without copy number variation
[6] have also been identified at the PLP1 locus. Our re-
sult further emphasizes the large diversity of the gen-
omic rearrangement involving the PLP1 gene probably
based on the complexity of the genomic architecture [7].
Finally, from a clinical point of view, careful consider-
ation should be given to girls with classical PMD clinical
features since they usually experience complex PLP1
genomic alteration with distinct risk of inheritance. FISH
analysis should thus be considered, in addition to copy
number evaluation and PLP1 gene sequencing, to detect
those complex rearrangements in girls with PMD.
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